Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fiona Gaughran

Showing results (171-180 of 190) with videos related to

Pageof 19
Sort By:
The British Journal of Psychiatry : the Journal of Mental Science|July 27, 2019
Effect of lifestyle, medication and ethnicity on cardiometabolic risk in the year following the first episode of psychosis: prospective cohort studyFiona Gaughran, Daniel Stahl, Dominic Stringer, et al.
Schizophrenia Research|August 7, 2025
Physical health among persons with untreated psychotic disorder in diverse settings of the Global SouthAkin Ojagbemi, Olufemi Idowu, Bola Olley, et al.
JAMA Network Open|December 28, 2021
Effect of Vitamin D Supplementation on Outcomes in People With Early Psychosis: The DFEND Randomized Clinical TrialFiona Gaughran, Dominic Stringer, Gabriella Wojewodka, et al.
Trials|September 30, 2016
STEPWISE - STructured lifestyle Education for People WIth SchizophrEnia: a study protocol for a randomised controlled trialRebecca Gossage-Worrall, Richard I G Holt, Katharine Barnard, et al.
BMC Psychiatry|December 24, 2017
Randomised controlled trial to improve health and reduce substance use in established psychosis (IMPaCT): cost-effectiveness of integrated psychosocial health promotionMargaret Heslin, Anita Patel, Daniel Stahl, et al.
Trials|January 8, 2020
Vitamin D supplementation compared to placebo in people with First Episode psychosis - Neuroprotection Design (DFEND): a protocol for a randomised, double-blind, placebo-controlled, parallel-group trialFiona Gaughran, Dominic Stringer, Michael Berk, et al.
Schizophrenia Bulletin|December 19, 2013
Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis usersMarta Di Forti, Hannah Sallis, Fabio Allegri, et al.
Schizophrenia Bulletin|December 10, 2024
Metformin for the Prevention of Antipsychotic-Induced Weight Gain: Guideline Development and Consensus ValidationAoife Carolan, Caroline Hynes-Ryan, Sri Mahavir Agarwal, et al.
The Lancet. Psychiatry|September 12, 2015
Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control studyMarta Di Forti, Arianna Marconi, Elena Carra, et al.
Journal of Medical Internet Research|October 28, 2021
Implementation, Adoption, and Perceptions of Telemental Health During the COVID-19 Pandemic: Systematic ReviewRebecca Appleton, Julie Williams, Norha Vera San Juan, et al.
Pageof 19

Showing results (171-180 of 190) with videos related to

Sort By:
Pageof 19
The British Journal of Psychiatry : the Journal of Mental Science|July 27, 2019
Effect of lifestyle, medication and ethnicity on cardiometabolic risk in the year following the first episode of psychosis: prospective cohort studyFiona Gaughran, Daniel Stahl, Dominic Stringer, et al.
Schizophrenia Research|August 7, 2025
Physical health among persons with untreated psychotic disorder in diverse settings of the Global SouthAkin Ojagbemi, Olufemi Idowu, Bola Olley, et al.
JAMA Network Open|December 28, 2021
Effect of Vitamin D Supplementation on Outcomes in People With Early Psychosis: The DFEND Randomized Clinical TrialFiona Gaughran, Dominic Stringer, Gabriella Wojewodka, et al.
Trials|September 30, 2016
STEPWISE - STructured lifestyle Education for People WIth SchizophrEnia: a study protocol for a randomised controlled trialRebecca Gossage-Worrall, Richard I G Holt, Katharine Barnard, et al.
BMC Psychiatry|December 24, 2017
Randomised controlled trial to improve health and reduce substance use in established psychosis (IMPaCT): cost-effectiveness of integrated psychosocial health promotionMargaret Heslin, Anita Patel, Daniel Stahl, et al.
Trials|January 8, 2020
Vitamin D supplementation compared to placebo in people with First Episode psychosis - Neuroprotection Design (DFEND): a protocol for a randomised, double-blind, placebo-controlled, parallel-group trialFiona Gaughran, Dominic Stringer, Michael Berk, et al.
Schizophrenia Bulletin|December 19, 2013
Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis usersMarta Di Forti, Hannah Sallis, Fabio Allegri, et al.
Schizophrenia Bulletin|December 10, 2024
Metformin for the Prevention of Antipsychotic-Induced Weight Gain: Guideline Development and Consensus ValidationAoife Carolan, Caroline Hynes-Ryan, Sri Mahavir Agarwal, et al.
The Lancet. Psychiatry|September 12, 2015
Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control studyMarta Di Forti, Arianna Marconi, Elena Carra, et al.
Journal of Medical Internet Research|October 28, 2021
Implementation, Adoption, and Perceptions of Telemental Health During the COVID-19 Pandemic: Systematic ReviewRebecca Appleton, Julie Williams, Norha Vera San Juan, et al.
Pageof 19